Biosensors

Biosensors: Religare initiates coverage with a BUY rating and $1.48 TP. Note that the co has emerged as a leading competitor in the US$6b global market for drug-eluding stents and expect it to continue gaining share by virtue of its innovative technology and strong position in Asia. Tip grp to Biosensors to continue gaining share in the drug-eluding stent (DES) market: with the co emerging as the industry's #4 player by virtue of technology advantages that address DES' clinical shortcomings. In addition, Biosensors' focus on faster-growing Asia Pacific markets (including China) should drive growth above the industry's 3-4% growth globally.